CompaniesBavarian Nordic

Bavarian Nordic

active

Kvistgard, Denmark

Founded 1994

Website

About

Vaccines

Areas of Focus

Categories

Biologics & BiopharmaceuticalVaccine

Clinical Trials (69)

View all

Total Trials

As Lead Sponsor

As Collaborator

Total Enrollment

52,309

By Phase

PHASE2: 26PHASE3: 17PHASE1: 18PHASE1/PHASE2: 4PHASE4: 2

By Status

COMPLETED: 53TERMINATED: 6RECRUITING: 4ACTIVE_NOT_RECRUITING: 3WITHDRAWN: 2NOT_YET_RECRUITING: 1

Clinical Trials Pipeline69 trials

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Phase 1/2

Phase 2/3

N/A

Phase

Status

Role

Condition

2000

2001

2002

2003

2004

2005

2006

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

Today

NCT00189943

Study on Safety, Tolerability and Immunogenicity of an MVA Vaccine Administered to Healthy Subjects

Phase: Phase 1

Role: Lead Sponsor

Start: Apr 30, 2001

Completion: Jul 31, 2003

NCT00189956

Dose-finding Study to Evaluate Immunogenicity of Three Different Dose Levels of the IMVAMUNE (MVA-BN) Smallpox Vaccine.

Phase: Phase 2

Role: Lead Sponsor

Start: Apr 30, 2003

Completion: Dec 31, 2005

NCT00189969

Take Rate, Immunogenicity and Safety of Elstree-BN Smallpox Vaccine in Healthy Vaccinia-Naive Subjects

Phase: Phase 1

Role: Lead Sponsor

Start: Sep 30, 2003

Completion: Feb 28, 2006

NCT00078585

PROSTVAC®-VF/TRICOM™ Vaccine for the Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy

Phase: Phase 2

Role: Lead Sponsor

Start: Nov 30, 2003

Completion: Jan 31, 2009

NCT00078585

NCT00189917

Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in Patients With Atopic Disorders

Phase: Phase 1

Role: Lead Sponsor

Start: Apr 30, 2004

Completion: Not specified

NCT00189917

NCT00189930

An Evaluation of Immunogenicity and Safety of Two Doses of MVA-nef vs. MVA-BN in HIV-1 Infected Patients

Phase: Phase 2

Role: Lead Sponsor

Start: Apr 30, 2005

Completion: Dec 31, 2006

NCT00189904

Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in HIV Infected Patients

Phase: Phase 1/2

Role: Lead Sponsor

Start: Jul 31, 2005

Completion: Not specified

NCT00189904

NCT00316524

A Randomized, Double-blind, Placebo-controlled Study on Immunogenicity and Safety of MVA-BN (IMVAMUNE™) Smallpox Vaccine in Healthy Subjects

Phase: Phase 2

Role: Lead Sponsor

Start: Apr 30, 2006

Completion: Aug 31, 2007

NCT00316589

Safety and Immunogenicity of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in HIV Infected Patients

Phase: Phase 2

Role: Lead Sponsor

Start: Jun 30, 2006

Completion: Oct 31, 2009

NCT00316602

A Phase II Study on Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in Subjects With Atopic Dermatitis

Phase: Phase 2

Role: Lead Sponsor

Start: Jul 31, 2006

Completion: Apr 30, 2010

NCT00386633

Safety and Immunogenicity Study of Recombinant Modified Vaccinia Virus Ankara (MVA) Virus to Treat HIV Infection

Phase: Phase 1

Role: Lead Sponsor

Start: Oct 31, 2006

Completion: Nov 30, 2007

NCT00390078

Single-Blind, Controlled Safety and Immunogenicity Study of Recombinant MVA Virus to Treat HIV Infection

Phase: Phase 1/2

Role: Lead Sponsor

Start: Jan 31, 2007

Completion: Jan 31, 2009

NCT00428337

Safety of and Immune Response to a DNA Vaccine and a Recombinant HIV-1-MVA Vaccine, Separately and in Combination, in Healthy Adults

Phase: Phase 1

Role: Collaborator

Start: Apr 30, 2007

Completion: Aug 31, 2008

NCT00485277

A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Metastatic Breast Cancer

Phase: Phase 1

Role: Lead Sponsor

Start: Jun 30, 2007

Completion: Sep 30, 2010

NCT00629057

A Safety Trial of MVA-BN®-PRO in Men With Androgen-Insensitive Prostate Cancer

Phase: Phase 1

Role: Lead Sponsor

Start: Mar 31, 2008

Completion: Sep 30, 2011

NCT00623259

Phase I Safety Study of a Recombinant MVA HIV Multiantigen Vaccine in HIV-infected Subjects

Phase: Phase 1

Role: Lead Sponsor

Start: May 31, 2008

Completion: Apr 30, 2009

NCT00686582

An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 Vaccinees

Phase: Phase 2

Role: Lead Sponsor

Start: Aug 31, 2008

Completion: Jun 30, 2009

NCT00857493

A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects

Phase: Phase 2

Role: Lead Sponsor

Start: Jun 30, 2009

Completion: Aug 31, 2010

NCT00891007

Study to Evaluate Safety, Dose Response and Immunogenicity of the Measles Vaccine MVA mBN85B in Healthy Children Aged 6 Months to 6 Years

Phase: Phase 2

Role: Lead Sponsor

Start: Jun 30, 2009

Completion: Aug 31, 2010

NCT03472014

Special Access Program IMVAMUNE®

Phase: Phase 4

Role: Lead Sponsor

Start: Apr 22, 2010

Completion: Nov 14, 2014

NCT03472014

NCT01152398

A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Breast Cancer After Adjuvant Therapy

Phase: Phase 1

Role: Lead Sponsor

Start: Jun 30, 2010

Completion: Sep 30, 2012

NCT01322490

A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer

Phase: Phase 3

Role: Lead Sponsor

Start: Nov 28, 2011

Completion: Dec 15, 2017

NCT01322490

NCT01585181

Safety and Immunogenicity of the Live Oral Cholera Vaccine Candidate PXVX0200

Phase: Phase 1

Role: Lead Sponsor

Start: Apr 30, 2012

Completion: Jan 31, 2013

NCT01144637

A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects

Phase: Phase 3

Role: Lead Sponsor

Start: Feb 28, 2013

Completion: Jun 30, 2014

NCT01668537

A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects

Phase: Phase 2

Role: Lead Sponsor

Start: Mar 31, 2013

Completion: Jun 30, 2014

NCT01895855

Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent Cholera

Phase: Phase 3

Role: Lead Sponsor

Start: Sep 30, 2013

Completion: Nov 30, 2014

NCT02038881

Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection

Phase: Phase 2

Role: Lead Sponsor

Start: Apr 28, 2014

Completion: May 10, 2017

NCT02094586

A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX0200 in Healthy Adults

Phase: Phase 3

Role: Lead Sponsor

Start: May 31, 2014

Completion: Jun 30, 2015

NCT02100631

A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults

Phase: Phase 3

Role: Lead Sponsor

Start: May 31, 2014

Completion: Jun 30, 2015

NCT01913353

A Non-inferiority Trial to Compare MVA-BN® Smallpox Vaccine to ACAM2000®

Phase: Phase 3

Role: Lead Sponsor

Start: Mar 31, 2015

Completion: Aug 31, 2017

NCT02391909

Phase 4 Study To Assess The Safety Of Vivotif At Different Release Titers Among Travelers

Phase: N/A

Role: Lead Sponsor

Start: Aug 26, 2015

Completion: Feb 21, 2017

NCT02419391

Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant MVA BN® RSV Vaccine

Phase: Phase 1

Role: Lead Sponsor

Start: Aug 31, 2015

Completion: May 31, 2016

NCT02661464

Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo

Phase: Phase 3

Role: Collaborator

Start: May 31, 2016

Completion: Dec 13, 2021

NCT02661464

NCT02772562

Adjuvant PROSTVAC-V/F in Subjects at High Risk for Relapse After Radical Prostatectomy

Phase: Phase 2

Role: Collaborator

Start: Jul 18, 2016

Completion: Apr 29, 2024

NCT02772562

NCT02864628

RSV-MVA-BN Vaccine Phase I Trial, Intranasal Application in Adults.

Phase: Phase 1

Role: Lead Sponsor

Start: Sep 30, 2016

Completion: Oct 27, 2017

NCT02873286

RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults

Phase: Phase 2

Role: Lead Sponsor

Start: Sep 30, 2016

Completion: Dec 31, 2018

NCT02506114

Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer

Phase: Phase 2

Role: Collaborator

Start: Oct 6, 2016

Completion: Apr 22, 2020

NCT02840994

A Trial of CV301 in Combination With Anti-PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer

Phase: Phase 1

Role: Lead Sponsor

Start: Dec 31, 2016

Completion: Jan 31, 2020

NCT02977715

JYNNEOS Smallpox Vaccine in Adult Healthcare Personnel at Risk for Mpox in the Democratic Republic of the Congo

Phase: Phase 3

Role: Collaborator

Start: Feb 23, 2017

Completion: Dec 31, 2025

NCT02977715

NCT03220737

VAXCHORA Pediatric Study to Assess Safety and Immunogenicity

Phase: Phase 4

Role: Lead Sponsor

Start: Jul 21, 2017

Completion: Mar 6, 2020

NCT03349983

Safety and Tolerability Trial (MVA-BN-Brachyury/FPV-Brachyury)

Phase: Phase 1

Role: Lead Sponsor

Start: Jan 8, 2018

Completion: Jun 13, 2020

NCT03483961

Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults

Phase: Phase 2

Role: Lead Sponsor

Start: Apr 18, 2018

Completion: Sep 21, 2020

NCT03547999

A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC

Phase: Phase 2

Role: Collaborator

Start: Jun 26, 2018

Completion: Mar 13, 2024

NCT03547999

NCT03376659

Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma

Phase: Phase 1/2

Role: Collaborator

Start: Aug 8, 2018

Completion: Aug 1, 2023

NCT03376659

NCT03532217

Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer

Phase: Phase 1

Role: Collaborator

Start: Sep 14, 2018

Completion: Jul 25, 2022

NCT03628716

CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer

Phase: Phase 2

Role: Lead Sponsor

Start: Sep 18, 2018

Completion: Feb 2, 2021

NCT03610581

Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix

Phase: Phase 1/2

Role: Collaborator

Start: Sep 27, 2018

Completion: Oct 15, 2020

NCT03745131

Cohort Study of Healthcare Workers Receiving Imvanex®

Phase: N/A

Role: Collaborator

Start: Oct 30, 2018

Completion: Nov 30, 2019

NCT03595228

BN Brachyury and Radiation in Chordoma

Phase: Phase 2

Role: Lead Sponsor

Start: Oct 31, 2018

Completion: Jan 25, 2022

NCT03699124

Freeze-Dried MVA-BN® Lot Consistency Smallpox Trial

Phase: Phase 3

Role: Lead Sponsor

Start: Jun 19, 2019

Completion: Jun 22, 2020

NCT04131595

Vaccination Trial of a Recombinant MVA-BN-WEV Vaccine in Healthy Adult Subjects

Phase: Phase 1

Role: Lead Sponsor

Start: Oct 7, 2019

Completion: Jul 22, 2020

NCT03992872

Phase 2 Open-label Study of Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317)

Phase: Phase 2

Role: Lead Sponsor

Start: Nov 20, 2019

Completion: Jan 19, 2021

NCT04020094

Perioperative Atezolizumab With MVA-BN-Brachyury and PROSTVAC For Intermediate-Risk And High-Risk Localized Prostate Cancer

Phase: Phase 2

Role: Collaborator

Start: Nov 20, 2019

Completion: Apr 9, 2021

NCT04134312

A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer

Phase: Phase 1

Role: Lead Sponsor

Start: Jan 8, 2020

Completion: Apr 6, 2021

NCT04246671

TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer

Phase: Phase 1

Role: Lead Sponsor

Start: Aug 10, 2020

Completion: Dec 11, 2024

NCT04752644

Phase 2a Study of MVA-BN-RSV Vaccination and RSV Challenge in Healthy Adults

Phase: Phase 2

Role: Lead Sponsor

Start: Feb 22, 2021

Completion: Nov 2, 2021

NCT05077267

ABNCoV2 Vaccine in SARS-CoV-2 (COVID-19) Seronegative and Seropositive Adult Subjects

Phase: Phase 2

Role: Lead Sponsor

Start: Aug 19, 2021

Completion: Oct 31, 2023

NCT05072080

A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP Vaccine)

Phase: Phase 3

Role: Lead Sponsor

Start: Sep 29, 2021

Completion: Apr 3, 2023

NCT05065983

A Study to Assess the Safety and Immunogenicity of PXVX0317 Chikungunya Virus Virus-Like Particle Vaccine

Phase: Phase 2

Role: Lead Sponsor

Start: Oct 11, 2021

Completion: May 5, 2022

NCT05238025

MVA-BN-RSV Vaccine Trial

Phase: Phase 3

Role: Lead Sponsor

Start: Apr 19, 2022

Completion: Sep 1, 2023

NCT05349617

Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 Years

Phase: Phase 3

Role: Lead Sponsor

Start: May 12, 2022

Completion: Aug 8, 2023

NCT05329220

ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2

Phase: Phase 3

Role: Lead Sponsor

Start: Aug 30, 2022

Completion: Oct 5, 2023

NCT06007183

Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination

Phase: Phase 3

Role: Lead Sponsor

Start: Aug 30, 2023

Completion: Aug 31, 2028

NCT06007183

NCT06549530

Open-label, Multicenter Immunogenicity and Safety Study of MVA-BN Vaccine in Children from 2 Years to Less Than 12 Years of Age Compared to Adults for the Prevention of Smallpox, Mpox, and Related Orthopoxvirus Infections

Phase: Phase 2

Role: Lead Sponsor

Start: Oct 21, 2024

Completion: May 7, 2026

NCT06899802

A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV Vaccine

Phase: Phase 2

Role: Lead Sponsor

Start: Mar 10, 2025

Completion: Mar 31, 2027

NCT06844487

Phase 3 Infant Safety & Immunogenicity Trial of MVA-BN® in DRC